The Modern Data Company and Thoughtworks Form Strategic Alliance to Accelerate Data Mesh Implementations and AI Initiatives
18.7.2023 13:12:00 EEST | Business Wire | Press release
The Modern Data Company, pioneers of the world's first data operating system, DataOS®, is thrilled to announce a strategic partnership with renowned global technology consultancy, Thoughtworks (NASDAQ: TWKS). This groundbreaking collaboration is set to reimagine data operations and accelerate the adoption of Data Products, Data Mesh, and AI initiatives across a wide range of industries.
Harnessing its rich expertise in data strategies, Thoughtworks has led numerous successful data transformation initiatives. The pairing of this experience with the technologically advanced Modern Data Company’s DataOS Platform--designed to streamline creation and management of Data Products, the key ingredients for a Data Mesh implementation--forms the backbone of this partnership. This collaborative alliance is set to unlock the full potential of organizational data, spearhead innovation, and pave the way for successful data modernization initiatives.
“The partnership between Modern and Thoughtworks marks a significant step as we transform how data is implemented and applied across an organization. We're changing the game by moving from traditional tables to a Data Product approach, and this collaboration significantly advances our shared vision. At The Modern Data Company, we firmly believe that the future lies in viewing and treating data as a product. This reimagining enables rapid, comprehensive creation and management of data, accelerating innovation and unlocking its full potential,” said Srujan Akula, CEO, The Modern Data Company. “By pairing Thoughtworks' profound expertise in data strategies with our innovative DataOS platform, we're poised to bring about a transformative shift in how organizations leverage their data.”
DataOS is an integrated platform that simplifies and expedites data development cycles. It equips teams with the comprehensive tools to easily build, manage, deploy, and iterate on their data products, all while ensuring seamless compatibility with the existing data infrastructure. This enables businesses to use their data assets without interruptions, maximizing derived value.
“The Modern Data Company and Thoughtworks have partnered to combine the world’s first data operating system, Modern’s DataOS, and Thoughtworks’ world-class data engineering and AI practices to help you thrive in today’s data-driven economy,” said John Spens, VP Data & AI Service Line, Thoughtworks. “Accelerate insights to drive your business by delivering transparent, trustworthy and accessible data efficiently and well.”
Stay tuned for more updates on this strategic partnership. For more information about The Modern Data Company and Thoughtworks, please visit their websites at https://TheModernDataCompany.com and https://Thoughtworks.com, respectively.
About The Modern Data Company:
The Modern Data Company offers comprehensive data management products. Our flagship product, DataOS®, is a data operating system pioneered to build comprehensive data products and accelerate the adoption of data mesh implementations so that organizations become truly data-driven and AI-ready.
See The Modern Data Company at CDOIQ 2023 in Cambridge, MA. at Booth #29 to learn more about data products and data mesh implementations.
About Thoughtworks
Thoughtworks is a global technology consultancy with more than 12,500 employees in 50 offices across 18 countries. It integrates strategy, design, and software engineering services for clients ranging from global Fortune 500 enterprises to digital natives and digital scaleups in industries like automotive, retail, financial services, healthcare, and the public sector. Founded in 1993, Thoughtworks is headquartered in Chicago.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230718888038/en/
Contact information
Press Contact:
Emanuel Younanzadeh
VP Marketing
The Modern Data Company
emanuel@tmdc.io
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom